[HTML][HTML] Ketogenic diets in pancreatic cancer and associated cachexia: cellular mechanisms and clinical perspectives
NE Cortez, GG Mackenzie - Nutrients, 2021 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and extremely therapy-resistant
cancer. It is estimated that up to 80% of PDAC patients present with cachexia, a multifactorial …
cancer. It is estimated that up to 80% of PDAC patients present with cachexia, a multifactorial …
[HTML][HTML] Hypoxic microenvironment induced spatial transcriptome changes in pancreatic cancer
H Sun, D Zhang, C Huang, Y Guo, Z Yang… - Cancer Biology & …, 2021 - ncbi.nlm.nih.gov
Objective: Hypoxia is a significant feature of solid tumors, including pancreatic ductal
adenocarcinoma (PDAC). It is associated with tumor invasion, metastasis, and drug …
adenocarcinoma (PDAC). It is associated with tumor invasion, metastasis, and drug …
[HTML][HTML] CRISPR-Cas9 screen identifies DYRK1A as a target for radiotherapy sensitization in pancreatic cancer
B Lan, S Zeng, S Zhang, X Ren, Y Xing, I Kutschick… - Cancers, 2022 - mdpi.com
Simple Summary Pancreatic cancer is the fourth leading cause of cancer-related death in
Western countries. Although several therapeutic strategies have been developed for …
Western countries. Although several therapeutic strategies have been developed for …
[HTML][HTML] Galanin 2 receptor: a novel target for a subset of pancreatic ductal adenocarcinoma
P Namsolleck, B Kofler, GN Moll - International Journal of Molecular …, 2023 - mdpi.com
Galanin is a 30 amino acid peptide that stimulates three subtype receptors (GAL1–3R).
M89b is a lanthionine-stabilized, C-terminally truncated galanin analog that specifically …
M89b is a lanthionine-stabilized, C-terminally truncated galanin analog that specifically …
[HTML][HTML] DA7R: a 7-letter Zip code to target PDAC
S Parrasia, A Rossa, N Roncaglia, A Mattarei… - Pharmaceutics, 2023 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer,
and is among the most aggressive and still incurable cancers. Innovative and successful …
and is among the most aggressive and still incurable cancers. Innovative and successful …
Identification of significant prognostic risk markers for pancreatic ductal adenocarcinoma: a bioinformatic analysis
Z Zhang, W Sun, Z Zeng, Y Lu - Acta Biochimica Polonica, 2022 - abp.ptbioch.edu.pl
Objective: This study aimed to identify novel prognostic biomarkers of pancreatic ductal
adenocarcinoma (PDAC) using bioinformatics analyzes. Methods: Clinical information …
adenocarcinoma (PDAC) using bioinformatics analyzes. Methods: Clinical information …
[PDF][PDF] Ketogenic Diets in Pancreatic Cancer and Associated Cachexia: Cellular Mechanisms and Clinical Perspectives. Nutrients 2021, 13, 3202
NE Cortez, GG Mackenzie - doi. org/10.3390 …, 2021 - pdfs.semanticscholar.org
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and extremely therapy-resistant
cancer. It is estimated that up to 80% of PDAC patients present with cachexia, a multifactorial …
cancer. It is estimated that up to 80% of PDAC patients present with cachexia, a multifactorial …
Le rôle de la cytidine désaminase dans le contrôle du stress réplicatif et de la résistance des cellules cancéreuses pancréatiques aux agents ciblant l'ADN
A Lumeau - 2021 - theses.hal.science
La cytidine désaminase (CDA) est impliquée dans le recyclage des pyrimidines, en
convertissant les cytidines et désoxycytidines en uridines et désoxyuridines, essentielles …
convertissant les cytidines et désoxycytidines en uridines et désoxyuridines, essentielles …
[HTML][HTML] CRISPR/Cas9 as a Treatment for Cancer
T Shaljian, C Barber - Journal of Student Research, 2023 - jsr.org
For decades, cancer treatments such as chemotherapy, radiotherapy, and surgery have
been used to treat various types of cancer. These treatments have also taken a significant …
been used to treat various types of cancer. These treatments have also taken a significant …